Abstract Neuroinflammation is heavily associated with various neurological diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. It is strongly characterized by the activation of microglia which can be visualized using position emission tomography (PET). Traditionally, translocator protein 18 kDa (TSPO) has been the preferred target for imaging the inflammatory progression of the microglial component. TSPO is expressed in the outer mitochondrial membrane and present in very low concentrations in the healthy human brain, but is markedly upregulated in response to brain injury and inflammation. Due to its value as a marker of microglial activation and subsequent utility for evaluating neuroinflammation in CNS disorders, several classes of TSPO radioligands have been developed and evaluated. However, the application of these secondgeneration TSPO radiotracers has been subject to several limiting factors, including a polymorphism that affects TSPO binding. This review focuses on recent developments in TSPO imaging, as well as current limitations and suggestions for future directions from a medical imaging perspective.
Introduction
Emerging evidence suggests that neuroinflammation is associated with a number of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and HIV-associated dementia, as well as stroke and neuro-psychiatric disorders [1] [2] [3] . Neuroinflammation is characterized by microglial activation, although astrocytes are also associated with neuroinflammation. Microglia are a type of glial cell present throughout the brain and spinal cord, and act as the primary line of immune defense for the central nervous system (CNS) [4] . The purpose of neuroinflammation is to localize and eliminate harmful agents and initiate tissue repair. However, in some cases, the process of neuroinflammation itself contributes to the development of disease. In response to various forms of neuronal damage within the CNS, microglia become activated and migrates to the site of injury, where they can undertake phagocytic and protective roles to maintain homeostasis and prevent further impairment [5] .
Inflammation can also contribute to the pathophysiology of epilepsy in the brain [6] . Epilepsy comprises a set of chronic neurological disorders characterized by seizures. Several studies have suggested that seizures promote inflammation in the brain, resulting in the upregulation of reactive microglial cells and astrocytes, and the production of pro-inflammatory cytokines such as interleukin (IL)-1, and IL-6, as well as tumor necrosis factor-alpha (TNFα) [7] . In addition, seizures can inflict damage on the blood brain barrier (BBB), which may contribute to further inflammation and hyper excitability via astrocyte involvement.
Positron emission tomography (PET) radiotracers have been developed to detect microglial activation and have proven to be useful as noninvasive molecular imaging tools to assess neuroinflammation. Over the past decade, several neuroinflammatory targets have been identified and their corresponding tracers developed. The translocator protein 18 kDa (TSPO) has emerged as the gold standard as the best PET imaging target for neuroinflammatory events in neurodegenerative diseases. Detection of this protein allows for the evaluation of activated microglia in the brain, and it was historically known as the peripheral-type benzodiazepine receptor (PBR). Existing as a hetero-oligomeric complex present on the outer mitochondrial membrane [8] , it interacts with various other proteins at the mitochondrial permeability transition pore (MPTP), including association with the voltagedependent anion channel (VDAC) and adenine nucleotide translocase (ANT), together with which it forms a transmembrane hyper structure [9, 10] .
A number of novel approaches in imaging technology have been developed for use in both animal models and humans. Among imaging modalities, PET is the most sensitive technique that can presently be used in vivo for detecting microglial activation and provides quantitative information based on a ligand-receptor interaction [11] . While the resting microglia has moderate TSPO expression in the healthly brain, it is precipitously increased in association with inflammatory disease and injury [12] . When microglia are activated in response to injury, an upregulation of mitochondrial TSPO expression typically occurs, which serves as a marker of inflammation associated with numerous neurological diseases including AD, PD, MS and stroke [13] [14] [15] . The use of selective and high-affinity TSPO radioligands together with PET represents powerful tools for visualizing the process of microglial activation in the living brain. Functionally, TSPO has been associated with several physiological processes including cholesterol transport, steroidogenesis, mitochondrial oxidation, cell growth and differentiation, neoplastic pathologies involving numerous types of cancer and neurodegenerative diseases. Therefore, TSPO has proved to be not only a therapeutic target but also a particularly relevant diagnostics target, leading to the development of specific radioligands and biomarkers of neuroinflammation of molecular imaging of PET.
The objective of this review is to summarize recent advances in PET imaging of activated microglia using TSPO ligands for the investigation of neurodegenerative diseases. A review of existing tracers, current limitations, emerging TSPO tracer development and suggestions for future direction are also explored.
PET Radioligands for TSPO
The development of new labeled TSPO ligands with shortlived positron-emitter isotopes 11 C and 18 F emerged in the mid-1980s. A number of these radiolabeled TSPO ligands have been developed for in vivo imaging, primarily in humans and mouse models [13] [14] [15] (Figs. 1 and 2 ).
First Generation TSPO Tracers in Neurologic Disease
Benzodiazepines Ro5-4864 is a 4′-chlorodiazepam-class molecule, and was the first ligand able to discriminate the peripheral benzodiazepine receptor from the central benzodiazepine receptor (CBR [17, 18] . These findings clearly indicate its limitations as a tool for TSPO PET imaging.
Isoquinoline Carboxamide
PK11195 is an isoquinoline carboxamide and in 1984 was the first non-benzodiazepine-type compound to be radiolabeled ([ 11 C]PK11195) [19] . It was initially used as a racemate with high affinity (K i = 9.3 nM) and selectivity to TSPO, and has since found utility in a number of animal and clinical studies [20] . Further in vivo studies determined that the (R)-enantiomer ([ 11 C](R)-PK11195) shows a twofold higher affinity in rats than the corresponding S-isomer, giving it superior properties for imaging studies [21] . Although both PK11195 and Ro5-4864 bind selectively to TSPO with nanomolar binding affinity, they differ substantially in their kinetics and pharmacological profiles, which exhibit saturable and reciprocal competitive binding properties. Furthermore, the maximum density and affinity characteristics of [ [22] . These ligands are thought to bind to heterogeneous sites on TSPO either in an overlapping or allosterically-coupled manner. Subsequent studies [ 11 C](R)-PK11195 have been successfully conducted for diseases as diverse as MS, AD, PD, amyotrophic lateral sclerosis (ALS), HIV, Rasmussen's encephalitis, herpes encephalitis, and neuropsychiatric disorders such as schizophrenia [23] (see [13] [14] [15] for review). Quantitative analysis of [ 11 C](R)-PK11195 in AD patients showed significantly increased binding in the entorhinal, temporoparietal, and cingulate cortex when compared with normal controls exhibiting only an age-dependent increase in the thalamus. Activation of the microglia, which correlates with the degree of uptake and disease progression, leads to progressive increases in TSPO binding, and is associated with early Alzheimer's pathogenesis [24] .
However, several kinetic and methodological issues have restricted the interpretation and potential use of this radioligand [6] . First, PK11195 has relatively low receptor affinity and engages in a high level of nonspecific binding due to its lipophilic nature, which leads to a poor signal to noise ratio and low specificity in PET imaging. Moreover, relatively low brain uptake and poor penetration of the BBB can further exacerbate this issue. Yet another issue is that 
11
C also has a very short half-life compared to 18 F, which has negative implications for more widespread clinical use.
Second Generation TSPO Tracers in Neurologic Disease
Extensive research efforts over the past decade have led to the development of several second generation TSPO ligands that have arisen from other structural classes, with superior C]DAA1106 is a novel class of phenoxyarylacetamide derivative with high specificity for TSPO, and was derived on the opening of the diazepine ring of Ro5-4864 [25] . As a second generation ligand, it has high affinity and selectivity for TSPO over [ [26] . Similar studies focusing on in vivo imaging of [ 11 C]DAA1106 in healthy mouse brain [27] and kainic acid-lesioned rats [28] [28] . Mean binding potential was significantly higher in the brains of AD patients when compared to their healthy control counterparts in areas of AD pathology including the dorsal and medial prefrontal cortex, parietal cortex, lateral temporal cortex, anterior cingulate cortex, occipital cortex, striatum, and cerebellum. The widespread increase in TSPO binding was visualized using [ 11 C]DAA1106 in the brains of AD patients at a relatively early stage [29] , suggesting that DAA1106 may overall be superior to PK11195. Moreover, in binding studies of AD patients [ [33] .
PBR28, an analog of DAA1106, was developed as a TSPO ligand with lower lipophilicity (cLogP = 3.01) than PK11195 (cLogP = 5.28) and DAA1106 (cLogP = 4.28) [34] . The in vivo specific binding of [ 11 C]PBR28 in monkey brain was 80-fold higher than that of [ 11 C](R)-PK11195, resulting in excellent signal to noise ratio and significantly more favorable pharmacokinetics [35] . It has been shown that high uptake of [ 11 C]PBR28 in specific areas of the monkey brain is consistent with known TSPO distribution in the same species [36] . Similar results have been demonstrated in a rat model of cerebral ischemia and stroke [37] . Moreover, studies with [ 11 C]PBR28 have led to a better understanding of the in vivo state of TSPO [38] . Initial studies have shown that approximately 10-20% of individual human subjects do not show appreciable specific binding for [ 11 C]PBR28 [35, 39] . This has a clear association with neuroinflammation in patients with temporal lobe epilepsy, suggesting an increased expression of TSPO. In addition, clinical studies have determined that epilepsy is associated with neuroinflammation, with brain uptake higher ipsilateral to the seizure focus in the hippocampus, parahippocampal gyrus, amygdala, fusiform gyrus, and choroid plexus, but not in other brain regions. Given the important clinical implications of this finding, further studies in a larger sample are warranted to confirm this finding and determine the clinical utility of TSPO imaging in the temporal lobe of epilepsy patients [40] .
Other promising candidates for TSPO labeling include
is a phenoxyphenyl acetamide derivative, which crosses the blood-brain barrier (BBB) in rats and accumulates in the occipital cortex of healthy monkeys. In vitro quantitative autoradiography studies have shown that DAA1097 has a similar binding affinity (K i = 0.19 ± 0.02 nM) with DAA1106 (K i = 0.09 ± 0.02 nM) and higher than PK11195 (K i = 0.54 ± 0.24 nM) for TSPO in the rat brain, suggesting that the bulky substitution is not favorable for binding affinity, and very good permeation of the BBB was observed [41] . Ex vivo autoradiography studies revealed that [ 11 C]DAA1097 is preferably distributed to the olfactory bulb and cerebellum, which are of a high density in the rat brain. [46] [47] [48] . It was demonstrated that increased neuroinflammation was not associated with normal aging, but rather that regional increased FEPPA uptake was associated with AD or PD [48, 49] . FEPPA displayed higher in vitro binding affinity (K i = 0.07 nM) compared to PBR28 (K i = 0.22 nM), DPA-713 (K i = 0.87 nM), and [ Upon intravenous injection into rats, moderate brain uptake and slow washout was observed. The highest uptake of radioactivity was in the TSPO-rich regions of the hypothalamus and olfactory bulb [43] . Furthermore, it showed a better association with severity of injury in the rat brain compared to [ 11 C](R)-PK11195, suggesting a higher affinity to TSPO and better brain transport [49] . However, quantitive interpretation of the PET signal with [ 18 F]FEPPA can be confounded by large inter-individual variability and differences in binding affinity [43] . [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] F-PBR28, an alternative fluorinated analogue of the PBR28 ligand, has been evaluated in binding affinity studies in vitro of 6- F-PBR28 was preferably distributed to the olfactory bulb and cerebellum, which are of a high density in the rat brain. The uptake of [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] F-PBR28 in the rat lesion striatum remained at a plateau until the end of the imaging procedure, while [ 
Vinyl Alkaloids
Vinpocetine, a vinca alkaloid, was initially used in the treatment of acute and chronic shock patients [53] . It was found to interfere with various stages of the ischemic cascade, and was thus developed as a carbon-11 PET ligand with more favorable pharmacokinetic characteristics and affinity toward TSPO. Vinpocetine binds to TSPO in brain tissue with low affinity in vitro (IC 50 = 0.2 μM) and was used for the pretreatment of two cynomolgous monkeys with vinpocetine reducing the uptake of [ [54] . These findings supported the hypothesis that the clinical neurological effects of vinpocetine may be due to its effect on microglial cells. It was also noted that it binds to other nonspecific receptors with a similar affinity to TSPO, raising questions about its in vivo specificity for TSPO [55] . A PET imaging study with four MS patients showed that, when compared with [ [56] . However, in an additional study in six AD patients and 12 healthy volunteers, there were no statistically significant differences between these uptake values in Alzheimer's patients and age-matched control subjects [57] . Another study comparing [
11 C]vinpocetine with [ 11 C](R)-PK11195 in stroke did not find evidence of any significant difference between the uptake of these two ligands in the peri-infarct zone, an area of established microglial activity [58] . This could be due to a low affinity of [ 11 C]vinpocetine for TSPO, which may limit its future clinical use.
Aryl-Oxodihydropurines
AC-5216 is an oxopurine and another second generation candidate with high affinity for the TSPO ligand [59] . It has more suitable lipophilicity (cLogP = 3.5) than PK11195 (cLogP = 5.1), which is required for a favorable PET ligand, guaranteeing high uptake and low nonspecific binding in the brain. AC-5216 showed potent displacement of [ 3 H]PK11195 binding in rat C6 (IC 50 = 3.04 nM) and human Hs638 (IC 50 = 2.73 nM) glioma cell-derived mitochondrial fractions [60] . The binding affinity of AC-5216 for TSPO in whole rat brain (K i = 0.297 nM) was higher than PK11195 (K i = 0.602 nM) [60] but lower than DA11106 (K i = 36∼108 pM) [61] . It has been successfully evaluated in several tumor models including a kainic acid rat model [59, 62] and murine fibrosarcoma models [63] . PET studies in monkey brain showed a high uptake of [ 11 C]AC-5216 in the occipital cortex, a rich TSPO-dense area in the primate brain [59] . PET studies in humans have demonstrated that the highest binding potential compared with undisplaceable uptake (BP ND ) is in the thalamus (4.6 ± 1.0) and the lowest is in the striatum (3.5 ± 0.7) [64] . The total distribution volume (V T ) obtained by nonlinear least-squares fitting (NLS) showed regional distribution similar to BP ND . However, there was no correlation between BP ND and V T due to inter-individual variation in K1/K2. BP ND data by NLS with a 60-min scan time were in good agreement with that from a scan time of 90 min (r = 0.87). Thus, BP ND is more appropriate for the quantification of [66] . It has a lower lipophilicity (logP = 2.4) compared to [ 11 C](R)-PK11195 (logP = 3.4), and good in vitro affinity for TSPO (K i = 4.7 vs 9.3 nM in rat kidney tissue). It was successfully evaluated in a variety of animal inflammation models and clinical studies [66] . In a PET study using an AMPA (amino-3-hydroxy-5-methyl-4-isoxazolepropionate) lesioned rat model of neuroinflammation, it was demonstrated that [ , which could be due to its highly specific binding with TSPO, which is useful in detecting changes in TSPO density [68] . PET studies in healthy human subjects showed that high uptake was observed throughout the brain and the dose-normalized uptake was up to three times greater than that of [ [79] .
[ 1 1 C]CB148 is an other analog ue of imid ia zo pyridineacetamide, which is selective for TSPO. It shows higher binding affinity (K i = 0.20 nM) compared to PK11195 (K i = 4.26 nM) in rat models, while distribution studies in mice show accumulation of radioactivity in TSPO-rich regions of the brain [80] . Moreover, the co-injection of either PK11195 or CB148 reduced the accumulation of this radioactivity in the brain. These results demonstrate that [ 11 C]CB148 maybe a useful radioligand and for the in vivo imaging of TSPO.
[ 18 F]CB251 is the imidazopyridineacetamide derivative that have been evaluated in animal models as potential imaging agents for human studies. CB251 display higher in vitro binding affinity (Ki = 0.27 nM) which was 22 and five times higher than the observed for PBR28 (Ki = 6.1 nM) and [ 3 H]PK11195 (Ki = 1.38 nM) in rat model. Furthermore, binding to CBR was below the detection limit, indicating the high selectivity of CB251 for TSPO. In PET imaging studies in neuroinflammatory rat model, [ 18 F]CB251 rapidly approaches the highest target to background ratio (2.7 times) at early imaging time and was selective accumulated in the ipsilateral striatum. The binding potential of the specifically bound ration ligand relative to the non-displaceable radioligand in tissue (BP ND = 1.83 ± 0.18) compared to that of [ [ 1 8 F]PBR111 is a metabolically-stable imidazo pyridineacetamide derivative which shows specificity for TSPO in a rodent model of acute neuroinflammation [82] . [ 18 F]PBR111 is a potent and selective TSPO inhibitor (K i =3.7 ± 0.4 nM) and has very low affinity for CBR (800 ± 0.4 nM) [83] . In vitro autoradiography of an AMPAlesioned brain showed that the target to background ratio (TBR) of [
18 F]PBR111 (3.9 ± 1.5) was double that of [ Despite the discovery of these second generation TSPO radiotracers, significant issues have emerged that limit their application for routine clinical use, including a low sensitivity and limited capacity to quantify suitable TSPO expression in vivo. Another concern for TSPO PET imaging is the lack of specificity of TSPO binding for activated microglia, which has necessitated the development of a new generation of radiotracers that target alternative markers of microglial activation.
New Generation TSPO Tracers in Neurologic Disease Tricyclic Radiotracers
Recent studies have shown that the indoleacetamide [ 11 C]SSR180575 is an effective TSPO PET tracer for the in vivo imaging of neuroinflammation. Moreover, its binding and imaging contrast are higher than that obtained with [ 11 C]PK11195 when distinguishing inflammatory tissue from healthy tissue [84] . The uptake ratio of ipsilateral to contralateral for [ 11 C]SSR180575 (2.75 ± 0.13) was higher than [ [85] .
The tricyclic compound, [ ]GE180) has a higher affinity for TSPO and better brain uptake and clearance compared to R-enantiomers and the racemate, due to differences in pharmacokinetics, efficacy, and potential toxicity. Furthermore, the S-enantiomer or ([ 18 F]GE-180) has also been shown to be enantiomerically stable in vivo and a promising agent for imaging neuroinflammation [86] . Its ability to bind selectively with high affinity to TSPO is important for the assessment of neuroinflammation in disease states, with significantly better TSPO imaging signal to noise ratio and lower nonspecific signal compared to the current gold standard [ ](R)-PK11195 PET radiotracer for imaging TSPO expression in response to neuroinflammation in a rodent model, which was generated by unilateral striatal injection of lipopolysaccharide (LPS) [88] . The superiority of the tracers was apparent for both in vivo and ex vivo imaging techniques, in which [ 18 F]GE-180) compared with saline injected animals (BP in vivo = 0.00) [88] . Therefore, the BP in vivo for [
18 F]GE-180 was higher than [ 11 C](R)-PK11195, enabling the visualization of sites of activated microglia in both gray and white matter. However, the signal increases in the presence of activated astrocytes.
A 
Limitations of New TSPO Radiotracers
Despite intensive efforts to explore neuroinflammation in clinical studies over the last decade, several limitations specifically associated with three properties of TSPO as a molecular biomarker of neuroinflammation have emerged.
Firstly, the investigation of second generation TSPO radioligands in human clinical studies has revealed the existence of 'non binders', referring to binding targets other than TSPO. Further studies have demonstrated that, with the exception of PK11195, all second-generation TSPO ligands in clinical use were influenced by the presence of non-binders in brain tissue in vitro, resulting in a lower affinity for TSPO. A common single nucleotide polymorphism (rs6971) in exon 4 of the TSPO gene causes an alanine to threonine substitution at A 147 T [92] . This polymorphism affects the ligand-binding affinity of TSPO and subsequent pregnenolone biosynthesis [93] . Three forms are expressed in relation to this polymorphism: Ala/Ala is associated with high affinity binding (HABs = 66% of the Caucasian population), whereas Ala/ Thr is associated with mixed affinity binding (=29%), while Thr/Thr is associated with low-affinity binding (LABs, = 5%), which determines the binding affinity of the ligands and causes large inter-subject variation in comparison to [ 11 C]PK11195. Importantly, this polymorphism can be identified by genetic analysis of leukocytes, allowing for the quantification of TSPO in PET studies using second generation radiotracers. This polymorphism was initially identified using non-radiolabeled PBR28 [92] and this has also been confirmed for [ 18 F]PBR111 [94] . Furthermore, polymorphism affects the predictions of [ 18 F]FEPPA total distribution volumes in the human brain. In addition, it results in clear differences between features in the shape of TACs and genetic binding groups [43] .
A second concern for the utility of TSPO is its nonspecificity for activated microglia, as it is also expressed by multiple types of immune cell including astrocytes. PET TSPO radiotracers are not able to distinction between proand anti-inflammation microglia, as it is expressed similarly in both activated astrocytes and microglia [95] . These two distinct activated states create significant limitations for data interpretation and in defining the role of microglia in neurologic disease. Therefore, the further development of new radiotracers that can target alternative markers of microglia activation are needed. Another issue with the development of these new generation radioligands in terms of optimal imaging results are the is that the quantification of data is a complex task. Microglia are distributed ubiquitously throughout the entire brain and in a disease state such neurodegenerative regions with a priori pathology may exist. Therefore, advanced methods using cluster analysis can be performed with dynamic PET scans of each individual to determine a suitable reference region.
Conclusion and Future Perspectives
Although TSPO has been a target of considerable focus in multiple studies over the past few decades, its mechanistic role in the pathophysiology of neurologic diseases remains to be fully understood. Recent evidence suggests that neuroinflammation plays a vital role in neurodegenerative disease including AD, PD, MS, and stroke [96] . TSPO expression in the brain has been considered a reliable marker of neuroinflammation, and is correlated with tissue damage such as neuronal loss. Microglial activation results in several molecular changes that affect both the structure and function of the TSPO. Although these studies provide evidence that physiological changes occur, including an increase in binding site density, as well as increased expression and polymerization, it may also result in additional site-binding interactions when considering those expressed by resting microglia. Therefore, the visualization of activated microglia based on PET is becoming increasingly important.
Several new high affinity and selective TSPO ligands labeled with the short-lived positron-emitter isotopes The identification of new targets specific for either proinflammatory or anti-inflammatory microglial phenotypes will provide further information on the role of these immune cells, and provide mechanistic rationale for the development of more effective neuroprotective drugs. More efforts for preclinical and clinical evaluation are needed to develop these radiotracers as therapeutic agents for the assessment of neurological and psychiatric disorders, to enable the development of novel drugs for the treatment of human disease.
